SCHEMBL1224946

SCHEMBL1224946

C1=Cc2cccc3cccc1c23.NS(=O)(=O)c1cnc2ccccc2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.44
LMNA P02545 4/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
CA1 P00915 4/20 0.40
CA2 P00918 4/20 0.40
CA12 O43570 3/20 0.40
CA9 Q16790 3/20 0.40
CA4 P22748 2/20 0.36
CA7 P43166 2/20 0.36
CA14 Q9ULX7 2/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CYP2C9 P11712 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL516558 0.84 HTT (0.57) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL27749003 0.74 HTT (0.47) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL5117540 0.68 HTT (0.54) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL3458498 0.68 HTT (0.57) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL30665799 0.68 HTT (0.57) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL3521038 0.68 HTT (0.58) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL11127797 0.67 HTT (0.53) HTTLMNAMAPTALDH1A1HPGD
Pyrazine SCHEMBL1198105 0.67 L3MBTL1 (0.33) HTTLMNAMAPTALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL28203639 0.66 HTT (0.56) HTTLMNAMAPTALDH1A1HPGD
SCHEMBL27914649 0.66 HTT (0.56) HTTLMNAMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof CRYSOPTIX K.K. (JP) 2009-07-30 US claimed
EP-1931644-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF Crysoptix Limited (CY) 2008-06-18 EP claimed
WO-2007042788-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF CRYSOPTIX LIMITED (CY) 2007-04-19 WO claimed
US-RE47117-E1 Compensated in-plane switching mode liquid crystal display CRYSOPTIX K.K. (JP) 2018-11-06 US disclosed
EP-2010949-B1 BACKLIGHT MODULE AND LIQUID CRYSTAL DISPLAY INCORPORATING THE SAME CRYSOPTIX KK (JP) 2014-09-10 EP disclosed
US-8416376-B2 Compensated in-plane switching mode liquid crystal display CRYSOPTIX KK (JP) 2013-04-09 US disclosed
US-7889297-B2 Liquid crystal display operating in a vertically aligned mode Crysoptix, KK (JP) 2011-02-15 US disclosed
US-20100149471-A1 Compensated In-Plane Switching Mode Liquid Crystal Display CRYSOPTIX KK (JP) 2010-06-17 US disclosed
US-20100118241-A1 Liquid Crystal Display Operating in a Vertically Aligned Mode CRYSOPTIX KK (JP) 2010-05-13 US disclosed
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof CRYSOPTIX K.K. (JP) 2009-07-30 US disclosed
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof CRYSOPTIX K.K. (JP) 2009-07-30 US disclosed
CN-101282947-A Acenaphthoquinoxaline sulfonamide derivative, optical crystal film and preparation method thereof CRYSOPTIX LTD (JP) 2008-10-08 CN disclosed
EP-1931644-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF Crysoptix Limited (CY) 2008-06-18 EP disclosed
EP-1931644-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF Crysoptix Limited (CY) 2008-06-18 EP disclosed
WO-2007141025-A2 LIQUID CRYSTAL DISPLAY OPERATING IN A VERTICALLY ALIGNED MODE CRYSOPTIX K.K. (JP) 2007-12-13 WO disclosed
WO-2007122389-A2 BACKLIGHT MODULE AND LIQUID CRYSTAL DISPLAY INCORPORATING THE SAME CRYSOPTIX K.K. (JP) 2007-11-01 WO disclosed
WO-2007042788-A3 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF CRYSOPTIX LTD (CY) 2007-09-07 WO disclosed
WO-2007083158-A2 MULTILAYER POLARIZER CRYSOPTIX K.K. (JP) 2007-07-26 WO disclosed
WO-2007042788-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF CRYSOPTIX LIMITED (CY) 2007-04-19 WO disclosed
WO-2007042788-A2 ACENAPHTHOQUINOXALINE SULFONAMIDE DERIVATIVES, OPTICAL CRYSTAL FILM AND METHOD OF PRODUCTION THEREOF CRYSOPTIX LIMITED (CY) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090191394-A1 Oarganic Compound, Optical Crystal Film and Method of Production Thereof HCN3, CFH, KCNH1 HTT 2568/4885LMNA 895/4885MAPT 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.